Food allergy—From food avoidance to active treatment

Costa, Célia; Coimbra, Alice; Vítor, Artur Bonito; Aguiar, Rita; Ferreira, Ana Rita; Todo-Bom, Ana

doi:10.1111/sji.12824

Cited by 31 publications

(17 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous research indicated positive effects of combining peanut OIT with an anti‐IgE treatment, such as omalizumab 8‐10 . Omalizumab lowers the sensitivity of mast cells and basophils, by capturing circulatory free IgE as well as downregulating the expression of the FcεRI on the basophils and mast cells and subsequently prevents the binding of IgE to the high‐affinity FcεRI on mast cells and basophils 11 .…”

Section: Introductionmentioning

confidence: 99%

A pilot study towards the immunological effects of omalizumab treatment used to facilitate oral immunotherapy in peanut‐allergic adolescents

et al. 2020

View full text Add to dashboard Cite

Anti‐IgE treatments, such as omalizumab, have shown promising effects in allergy treatment. Our previous work has shown that individualized omalizumab treatment (OT) allows a safe initiation and rapid up‐dosing of peanut oral immunotherapy (OIT) in peanut‐allergic adolescents. However, the broader immunological effects of this OT are incompletely understood. In this pilot study, we longitudinally followed the total B‐ and T‐cell immunity during OT, using flow cytometry, ELISpot and ELISA. Peripheral blood mononuclear cells (PBMCs) and plasma were collected from participants (n = 17) at several timepoints during treatment, before starting OT (baseline), prior to starting OIT during OT (start OIT) and at maintenance dose OIT prior to OT reduction (maintenance). OT did not affect the total B‐cell compartment over treatment time, but our results suggest an association between the OT dosage scheme and the B‐cell compartment. Further, in vitro polyclonal T‐cell activation at the different timepoints suggests a cytokine skewing towards the Th1 phenotype at the expense of Th2‐ and Th9‐related cytokines during treatment. No differences in the frequencies or phenotype of regulatory T cells (Tregs) over treatment time were observed. Finally, plasma chemokine levels were stable over treatment time, but suggest elevated gut homing immune responses in treatment successes during the treatment as compared to treatment failures. The novel and explorative results of this pilot study help to improve our understanding on the immunological effects of OT used to facilitate OIT and provide guidance for future immunological investigation in large clinical trials.

show abstract

Section: Introductionmentioning

confidence: 99%

A pilot study towards the immunological effects of omalizumab treatment used to facilitate oral immunotherapy in peanut‐allergic adolescents

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Therefore, the transfer from food avoidance to active treatment is essential. Omalizumab and oral immunotherapy have been used for treating IgE-mediated food allergy, which has shown the potential to be used for CMPA treatment (Inuo et al, 2018;Costa et al, 2020). Nowadays, a few other active treatment strategies, such as probiotics and prebiotics (Qamer et al, 2019), transplantation of fecal microbiota (Feehley et al, 2019), and precise personalized designed diets, have been developed for the treatment of infants with CMPA (Figure 2).…”

Section: Probiotics Prebiotics and Cmpamentioning

confidence: 99%

Advances in the Relationships Between Cow’s Milk Protein Allergy and Gut Microbiota in Infants

Yang

Ying

et al. 2021

Front. Microbiol.

View full text Add to dashboard Cite

Cow’s milk protein allergy (CMPA) is an immune response to cow’s milk proteins, which is one of the most common food allergies in infants and young children. It is estimated that 2–3% of infants and young children have CMPA. The diet, gut microbiota, and their interactions are believed to be involved in the alterations of mucosal immune tolerance, which might lead to the development of CMPA and other food allergies. In this review, the potential molecular mechanisms of CMPA, including omics technologies used for analyzing microbiota, impacts of early microbial exposures on CMPA development, and microbiota–host interactions, are summarized. The probiotics, prebiotics, synbiotics, fecal microbiota transplantation, and other modulation strategies for gut microbiota and the potential application of microbiota-based design of diets for the CMPA treatment are also discussed. This review not only summarizes the current studies about the interactions of CMPA with gut microbiota but also gives insights into the possible CMPA treatment strategies by modulating gut microbiota, which might help in improving the life quality of CMPA patients in the future.

show abstract

“…It is understood that the key management for the long-term treatment of patients with a food allergy is food avoidance [122]. The biggest concern of this approach is the high risk of malnutrition and further exacerbating feeding difficulties among children [123], especially in picky eaters.…”

Section: Personalized Nutrition In the Management Of Food Allergymentioning

confidence: 99%

The Interplay of Nutriepigenomics, Personalized Nutrition and Clinical Practice in Managing Food Allergy

Ali

Hamzaid

Ismail

2021

Life

View full text Add to dashboard Cite

Food allergy in children has been a common issue due to the challenges of prescribing personalized nutrition with a lack of nutriepigenomics data. This has indeed further influenced clinical practice for appropriate management. While allergen avoidance is still the main principle in food allergy management, we require more information to advance the science behind nutrition, genes, and the immune system. Many researchers have highlighted the importance of personalized nutrition but there is a lack of data on how the decision is made. Thus, this review highlights the relationship among these key players in identifying the solution to the clinical management of food allergy with current nutriepigenomics data. The discussion integrates various inputs, including clinical assessments, biomarkers, and epigenetic information pertaining to food allergy, to curate a holistic and personalized approach to food allergy management in particular.

show abstract

Food allergy—From food avoidance to active treatment

Cited by 31 publications

References 106 publications

A pilot study towards the immunological effects of omalizumab treatment used to facilitate oral immunotherapy in peanut‐allergic adolescents

A pilot study towards the immunological effects of omalizumab treatment used to facilitate oral immunotherapy in peanut‐allergic adolescents

Advances in the Relationships Between Cow’s Milk Protein Allergy and Gut Microbiota in Infants

The Interplay of Nutriepigenomics, Personalized Nutrition and Clinical Practice in Managing Food Allergy

Contact Info

Product

Resources

About